Detection of Antibodies against


Accuracy rate > 99%

Very high accuracy

Fast, easy and safe to use

No equipment requirement

Can monitor all phases of covid-19

High sensitivity


Immunoglobulin M (IgM), which is found mainly in the blood and lymph fluid, is the first antibody to be made by the body to fight a new infection (the acute phase). IgM can be tested and detected very early after infection and disappears within 1 to 2 months after the infection (see the graph below).
Immunoglobulin G (IgG), the most abundant type of antibody, is found in all body fluids and protects against for example bacterial and viral infections. IgG is the antibody being produced from the middle -, and through the infection period all the way into the late stage infection (see the graph below). It is also this immunoglobulin-type which will be synthesized as a response to a new infection with SARS-CoV-2 and try to destroy the infection process. Therefore, a positive result for IgG indicates that the patient is either recovering or has had a previous infection.


Add 20uL ( 1 drop)
Specimen into the “S” well

Add 2 drops sample
diluent into the “S” well

Report the results
in 10-15 minutes.


NOTE: Only tests with a clear colored line in the control test line region C (C) are valid


At least a colored line appears in the test line region G (G: the test person expresses Ab(IgGhuman(SARS-CoV-2))) or in the test line region M (M: the test person expresses Ab(IgMhuman(SARS-CoV-2)).
If both a colored line appears in the test line region G and region M it indicates that the test person expresses both Ab(IgMhuman(SARS-CoV-2)) and Ab(IgGhuman(SARS-CoV-2))

NOTE: The intensity of the color in the test line region(s) (G and M) will vary depending on the concentration of SARS-CoV-2 antibodies in the specimen. Therefore, any shade of color in the test line region(s) (G and M) should be considered positive.


No line appears in test line regions G and M (G and M).


Control line fails to appear.
Insufficient specimen volume or incorrect procedure for the test are the most likely reasons for control line failure.
Review the procedure and repeat the test with a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.


The Diagnostic Kit for IgG and IgM Antibodies against SARS-CoV-2 is a qualitative membrane-based immunoassay for the detection of SARS-CoV-2 antibodies in whole blood, serum, or plasma. This test consists of two components, an IgG component and an IgM component. The test line region is coated with antibodies against human IgM (Ab(IgMhuman)) and human IgG (Ab(IgGhuman)), respectively. During testing, the specimen (whole blood, serum or plasma) reacts with SARS-CoV-2 antigen-coated particles (Ag(SARS-CoV-2)-Particle) in the test strip.

If the specimen contains antibodies against SARS-CoV-2 (Ab(IgMhuman(SARS-CoV-2)) and/or Ab(IgGhuman(SARS-CoV-2))) they will react with the Ag(SARS-CoV-2)-Particles and form the complexes:




The mixture will then migrate upward on the membrane due to chromatographically, capillary action and reacts with the bound Ab(IgMhuman) and Ab(IgGhuman) in the test line region. The complexes in the specimen will then bind to the bound Ab(IgMhuman) and Ab(IgGhuman), respectively.
The following complexes will be formed:

Ab(IgMhuman)=Ab(IgMhuman(SARS-CoV-2)=Ag(SARS-CoV-2)-Particles       (Line M)


Ab(IgGhuman)=Ab(IgGhuman(SARS-CoV-2))=Ag(SARS-CoV-2)-Particles       (Line G)

It is important to remember that a patient can easily be positive in both Lines M and G, respectively, if the patient is more or less in the middle of the infection episode with SARS-CoV-2. Later the IgM-response will fade out and the IgG-response will increase in intensity.


Kit Size: 16*14.5*8cm
25 tests / kit
Kit weight: 272g
30 kits in a box
Box Size: 455mm*345mm*435mm
Box weight: 9.33kg

Frequently Asked Questions

Who is at risk of developing severe illness?

While we are still learning about how COVID-2019 affects people, older persons and persons with pre-existing medical conditions (such as high blood pressure, heart disease, lung disease, cancer or diabetes)  appear to develop serious illness more often than others. 

Is there a vaccine, drug or treatment for COVID-19?

Not yet. To date, there is no vaccine and no specific antiviral medicine to prevent or treat COVID-2019. However, those affected should receive care to relieve symptoms. People with serious illness should be hospitalized. Most patients recover thanks to supportive care.

Possible vaccines and some specific drug treatments are under investigation. They are being tested through clinical trials. WHO is coordinating efforts to develop vaccines and medicines to prevent and treat COVID-19.

The most effective ways to protect yourself and others against COVID-19 are to frequently clean your hands, cover your cough with the bend of elbow or tissue, and maintain a distance of at least 1 meter (3 feet) from people who are coughing or sneezing. (See Basic protective measures against the new coronavirus).

Is COVID-19 the same as SARS?

No. The virus that causes COVID-19 and the one that caused the outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003 are related to each other genetically, but the diseases they cause are quite different.

SARS was more deadly but much less infectious than COVID-19. There have been no outbreaks of SARS anywhere in the world since 2003.

Ask a Question




+41 435 880 619


Hagenholzstrasse 83b
CH-8050 Zürich